Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens.

Mycobacterium microti, the vole bacillus, which was used as a live vaccine against tuberculosis until the 1970s, confers the same protection in humans as does Mycobacterium bovis bacille Calmette-Guerin (BCG). However, because the efficacy of the BCG vaccine varies considerably, we have tried to develop a better vaccine by reintroducing into M. microti the complete region of difference 1 (RD1), which is required for secretion of the potent T cell antigens early secreted antigen target (ESAT)-6 and culture filtrate protein (CFP)-10. The resultant recombinant strain, M. microti OV254::RD1-2F9, induced specific ESAT-6 and CFP-10 immune responses in mice with CD8(+) T lymphocytes that had strong expression of the CD44(hi) activation marker. This vaccine also displayed better efficacy against disseminated disease in the mouse and the guinea pig models of tuberculosis than was seen in animals vaccinated with M. microti alone or with BCG. The M. microti OV254::RD1-2F9 vaccine was less virulent and persistent in mice and than was BCG::RD1-2F9 may represent a safer alternative to BCG::RD1-2F9.

[1]  S. Cole,et al.  Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis , 2003, Nature Medicine.

[2]  J. Deeks,et al.  Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak , 2003, The Lancet.

[3]  L. Bao,et al.  Virulence, Immunogenicity, and Protective Efficacy of Two Recombinant Mycobacterium bovis Bacillus Calmette-Guérin Strains Expressing the Antigen ESAT-6 from Mycobacterium tuberculosis , 2003, Infection and Immunity.

[4]  S. Gordon,et al.  Identification of Novel Mycobacterium tuberculosis Antigens with Potential as Diagnostic Reagents or Subunit Vaccine Candidates by Comparative Genomics , 2002, Infection and Immunity.

[5]  Priscille Brodin,et al.  Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti , 2002, Molecular microbiology.

[6]  S. Cole,et al.  Bacterial Artificial Chromosome-Based Comparative Genomic Analysis Identifies Mycobacterium microti as a Natural ESAT-6 Deletion Mutant , 2002, Infection and Immunity.

[7]  C. Buchrieser,et al.  A new evolutionary scenario for the Mycobacterium tuberculosis complex , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[8]  A. Bean,et al.  Lymphocyte Recruitment and Protective Efficacy against Pulmonary Mycobacterial Infection Are Independent of the Route of Prior Mycobacterium bovis BCG Immunization , 2002, Infection and Immunity.

[9]  W. Bishai,et al.  Naturally Attenuated, Orally Administered Mycobacterium microti as a Tuberculosis Vaccine Is Better than Subcutaneous Mycobacterium bovis BCG , 2002, Infection and Immunity.

[10]  J. Flynn,et al.  CD8+ T Cells Participate in the Memory Immune Response to Mycobacterium tuberculosis , 2001, Infection and Immunity.

[11]  G. Bancroft,et al.  Characterization of Auxotrophic Mutants ofMycobacterium tuberculosis and Their Potential as Vaccine Candidates , 2001, Infection and Immunity.

[12]  W. Jacobs,et al.  Identification of a Mycobacterium bovisBCG Auxotrophic Mutant That Protects Guinea Pigs against M. bovis and Hematogenous Spread of Mycobacterium tuberculosis without Sensitization to Tuberculin , 2000, Infection and Immunity.

[13]  W. Bishai,et al.  Efficacies of BCG and vole bacillus (Mycobacterium microti) vaccines in preventing clinically apparent pulmonary tuberculosis in rabbits: a preliminary report. , 2000, Vaccine.

[14]  D. Collins,et al.  An esat6 knockout mutant of Mycobacterium bovis produced by homologous recombination will contribute to the development of a live tuberculosis vaccine. , 2000, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[15]  R. G. Hewinson,et al.  Comparison of the protective efficacy of bacille calmette-Guérin vaccination against aerosol challenge with Mycobacterium tuberculosis and Mycobacterium bovis. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  P. Marsh,et al.  The physiology and pathogenicity of Mycobacterium tuberculosis grown under controlled conditions in a defined medium , 2000, Journal of applied microbiology.

[17]  P. Andersen,et al.  ESAT-6 Subunit Vaccination againstMycobacterium tuberculosis , 2000, Infection and Immunity.

[18]  G. Schoolnik,et al.  Comparative genomics of BCG vaccines by whole-genome DNA microarray. , 1999, Science.

[19]  P. Andersen,et al.  B-Cell Epitopes and Quantification of the ESAT-6 Protein of Mycobacterium tuberculosis , 1998, Infection and Immunity.

[20]  C. L. Silva,et al.  Identification and Characterization of Protective T Cells in hsp65 DNA-Vaccinated and Mycobacterium tuberculosis-Infected Mice , 1998, Infection and Immunity.

[21]  P. Andersen,et al.  Key epitopes on the ESAT-6 antigen recognized in mice during the recall of protective immunity to Mycobacterium tuberculosis. , 1996, Journal of immunology.

[22]  P. E. M. Fine,et al.  Variation in protection by BCG: implications of and for heterologous immunity , 1995, The Lancet.

[23]  K. Huygen,et al.  Mapping of TH1 helper T-cell epitopes on major secreted mycobacterial antigen 85A in mice infected with live Mycobacterium bovis BCG , 1994, Infection and immunity.

[24]  C. Leclerc,et al.  Identification of a T-cell epitope adjacent to neutralization antigenic site 1 of poliovirus type 1 , 1991, Journal of virology.

[25]  P. D. Hart,et al.  BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. , 1977, British medical journal.

[26]  THE MURINE TYPE OF TUBERCLE BACILLUS , 1947 .

[27]  A. Griffith.  The cultural characters and pathogenicity for some laboratory animals of the vole strain of acid-fast bacillus , 1942, Epidemiology and Infection.

[28]  Griffith As.  The cultural characters and pathogenicity for some laboratory animals of the vole strain of acid-fast bacillus , 1942 .

[29]  A. Q. Wells.  Tuberculosis in Wild Voles , 1937, Nature.

[30]  D. Sherman,et al.  Deletion of RD1 from Mycobacterium tuberculosis mimics bacille Calmette-Guérin attenuation. , 2003, The Journal of infectious diseases.

[31]  W. Britton,et al.  Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. , 1999, Infection and immunity.

[32]  L. Šula,et al.  Protective effects of M. microti vaccine against tuberculosis. , 1976, Journal of hygiene, epidemiology, microbiology, and immunology.

[33]  A. Q. Wells,et al.  Vaccination against tuberculosis with the vole bacillus. , 1954, British medical bulletin.

[34]  A. Calmette.  La vaccination preventive contre la tuberculose par le "BCG" , 1927 .